NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 23.
BANK OVERDRAFTS AND LOANS As at 31 December 2012 2011 $000 $000 Bank overdrafts 19,591 18,286 port and export financing 72,768 53,196 Im Short-term loans 12,011 4,284 Deferred consideration 11,785 Current portion of long-term loans Note 26 88,509 65,302 192,879 152,853 2012 2011 % % The weighted average interest rates paid were as follows: Bank overdrafts 5.24 4.80 Bank loans including the non-current bank loans 3.07 2.94 Import and export financing 3.69 2.42 Import and export nancing represents short-term nancing for the ordinary trading activities of the business.
The deferred consideration is in relation to the acquisition of MSI and was paid during the year ended 31 December 2012.
TRADE AND OTHER PAYABLES As at 31 December 2012 2011 $000 $000 Trade payables 110,600 97,756 Accrued expenses 69,734 60,276 Employees provident fund 5,863 4,181 AT and sales tax payables 560 535 V Dividends payable 2,074 2,207 Social security withholdings 1,709 1,107 Income tax withholdings 2,862 2,482 Other payables 1,403 668 194,805 169,212 The employees provident fund liability mainly represents the outstanding contributions due to the Hikma Pharmaceuticals Ltd Jordan retirement benefit plan, on which the fund receives 5% interest.
Dividends payable includes $1,889,000 2011: $2,022,000 due to the previous shareholders of APM.
OTHER PROVISIONS Other provisions represent the end of service indemnity provisions of certain Hikma Group subsidiaries.
This provision is calculated based on relevant laws in the countries where each Group company operates, in addition to their own policies.
Movements on the provision for end of service indemnity: 2012 2011 $000 $000 1 January 9,398 8,641 Additions 2,069 1,865 Utilisation 767 1,069 Translation adjustments 36 39 31 December 10,664 9,398 142 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
